1. Didkowska J, Barańska K, Miklewska MJ, Wojciechowska U. Cancer incidence and mortality in Poland in 2023. Nowotwory J Oncol 2024; 74: 75-93.
2.
Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet 2011; 378: 607-20.
3.
Conroy T, Pfeiffer P, Vilgrain V, et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34: 987-1002.
4.
National Comprehensive Cancer Network (NCCN). Pancreatic Adenocarcinoma, Version 2.2025. 2025.
5.
Springfeld C, Bailey P, Büchler MW, Neoptolemos JP. ESMO 2023 pancreatic cancer guidelines signal stepwise progress. Hepatobiliary Surg Nutr 2024; 13: 362-5.
6.
Cortiana V, Abbas RH, Chorya H, et al. Personalized medicine in pancreatic cancer: the promise of biomarkers and molecular targeting with Dr. Michael J. Pishvaian. Cancers 2024; 16: 2329.
7.
Bärthel S, Falcomatà C, Rad R, et al. Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy. Nat Cancer 2023; 4: 454-67.
8.
Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med 2017; 377: 2500-1.
9.
Raphael BJ, Hruban RH, Aguirre AJ, et al. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 2017; 32: 185-203.
10.
Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015; 518: 495-501.
11.
Maple JT, Smyrk TC, Boardman LA, et al. Defective DNA mismatch repair in long-term (≥ 3 years) survivors with pancreatic cancer. Pancreatology 2005; 5: 220-8.
12.
Fraune C, Burandt E, Simon R, et al. MMR deficiency is homogeneous in pancreatic carcinoma and associated with high density of Cd8-positive lymphocytes. Ann Surg Oncol 2020; 27: 3997-4006.
13.
Campbell PJ, Yachida S, Mudie LJ, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010; 467: 1109-13.
14.
Pishvaian MJ, Blais EM, Brody JR, et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol 2020; 21: 508-18.
15.
Qu S, Xu R, Yi G, et al. Patient-derived organoids in human cancer: a platform for fundamental research and precision medicine. Mol Biomed 2024; 5: 6.
16.
Sereti E, Papapostolou I, Dimas K. Pancreatic cancer organoids: an emerging platform for precision medicine? Biomedicines 2023; 11: 890.
17.
Huang L, Holtzinger A, Jagan I, et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell– and patient-derived tumor organoids. Nat Med 2015; 21: 1364-71.
18.
Tiriac H, Belleau P, Engle DD, et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov 2018; 8: 1112-29.
19.
Driehuis E, van Hoeck A, Moore K, et al. Pancreatic cancer organoids recapitulate disease and allow personalized drug screening. Proc Natl Acad Sci 2019; 116: 26580-90.
20.
Walsh AJ, Castellanos JA, Nagathihalli NS, et al. Optical imaging of drug-induced metabolism changes in murine and human pancreatic cancer organoids reveals heterogeneous drug response. Pancreas 2016; 45: 863-9.
21.
Sharick JT, Walsh CM, Sprackling CM, et al. Metabolic heterogeneity in patient tumor-derived organoids by primary site and drug treatment. Front Oncol 2020; 10: 553.
22.
Seppälä TT, Zimmerman JW, Suri R, et al. Precision medicine in pancreatic cancer: patient-derived organoid pharmacotyping is a predictive biomarker of clinical treatment response. Clin Cancer Res 2022; 28: 3296-307.
23.
Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent ipilimumab (Anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010; 33: 828-33.
24.
Balachandran VP, Łuksza M, Zhao JN, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 2017; 551: 512-6.
25.
Łuksza M, Sethna ZM, Rojas LA, et al. Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature 2022; 606: 389-95.
26.
Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 2023; 618: 144-50.
27.
Masum MHU, Wajed S, Hossain MI, et al. An mRNA vaccine for pancreatic cancer designed by applying in silico immunoinformatics and reverse vaccinology approaches. PLoS One 2024; 19: e0305413.
